[{"orgOrder":0,"company":"Antabio","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"ANT3310","moa":"||Serine beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Antabio \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Bpifrance"},{"orgOrder":0,"company":"Antabio","sponsor":"Carb-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Pseudomonas elastase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Antabio \/ Carb-X","highestDevelopmentStatusID":"1","companyTruncated":"Antabio \/ Carb-X"},{"orgOrder":0,"company":"Antabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ANT3310","moa":"||Serine beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antabio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antabio \/ Inapplicable"},{"orgOrder":0,"company":"Antabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ANT3310","moa":"||Serine beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Antabio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor.

                          Product Name : ANT3310

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2023

                          Lead Product(s) : ANT3310,Meropenem

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The funding for Antabio will allow to continue the development of ANT3310 towards clinical studies and reach crucial milestones such as the clinical demonstration of its safety and tolerability in humans.

                          Product Name : ANT3310

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 01, 2022

                          Lead Product(s) : ANT3310,Meropenem

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Bpifrance

                          Deal Size : $10.0 million

                          Deal Type : Funding

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : QIDP is granted to Antabio's MEM-ANT3310 for major hospital indications including nosocomial pneumonia.

                          Product Name : ANT3310

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 05, 2020

                          Lead Product(s) : ANT3310,Meropenem

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The funding is to support the development of Antabio's novel small molecule candidate for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 01, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Carb-X

                          Deal Size : $4.4 million

                          Deal Type : Funding

                          blank